Fine needle aspiration biopsy in low‐ and middle‐income countries
Diagnostic Cytopathology · 2024-08 · 52 (8) · 426-432
DOI: 10.1002/dc.25317 ↗At a glance
Übersichtsarbeit in Diagnostic Cytopathology, published online on 2024-04-04. Written by Nikka Khorsandi and 2 co-authors. Institution: Department of Pathology, University of California, San Francisco, California, USA. Major MEDLINE topics: Developing Countries. Cited 5 times so far (Crossref); 50 references.
Abstract (original language)
Fine needle aspiration biopsy (FNAB) in low‐ and middle‐income countries (LMIC), can provide minimally invasive, cost‐effective tissue diagnosis with rapid assessment and specimen triage, which is advantageous in these resource‐limited settings. Nevertheless, challenges such as equipment shortages, reagents, and lack of trained personnel exist. This article discusses the effectiveness of FNAB for diagnosis of malignant and inflammatory conditions across various organs, such as lymph nodes, breast, soft tissue, and thyroid and advocates for increased training opportunities and collaboration with academic centers to enhance diagnostic accuracy and access to pathology services.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Pathology, University of California, San Francisco, California, USA.
ORCID profiles: Poonam Vohra
Cite
APA
Khorsandi, N., Balassanian, R., & Vohra, P. (2024). Fine needle aspiration biopsy in low‐ and middle‐income countries. Diagnostic Cytopathology, 52(8), 426-432. https://doi.org/10.1002/dc.25317
Vancouver
Khorsandi N, Balassanian R, Vohra P. Fine needle aspiration biopsy in low‐ and middle‐income countries. Diagnostic Cytopathology. 2024;52(8):426-432. doi:10.1002/dc.25317
BibTeX
@article{Khorsandi2024,
author = {Khorsandi, Nikka and Balassanian, Ron and Vohra, Poonam},
title = {Fine needle aspiration biopsy in low‐ and middle‐income countries},
journal = {Diagnostic Cytopathology},
year = {2024},
volume = {52},
number = {8},
pages = {426--432},
doi = {10.1002/dc.25317}
}
EUVIMED